{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:36:25Z","timestamp":1789436185858,"version":"build-2803163510"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jaad.2023.03.057","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T01:47:23Z","timestamp":1681523243000},"page":"408-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medications affecting the insulin-like growth factor 1\/growth hormone axis, including teprotumumab, somatostatin analogs, and anti-calcitonin gene-related peptide monoclonal antibodies, are associated with elevated reporting odds of alopecia in women: A pharmacovigilance study"],"prefix":"10.1016","volume":"89","author":[{"given":"Patrick Michael","family":"Jedlowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdieh F.","family":"Jedlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Fazel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.jaad.2023.03.057_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413205","article-title":"Growth hormone and the human hair follicle","volume":"22","author":"Horesh","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.jaad.2023.03.057_bib2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2021.04.024","article-title":"Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies","volume":"128","author":"Winn","year":"2021","journal-title":"Ophthalmology"},{"issue":"Suppl","key":"10.1016\/j.jaad.2023.03.057_bib3","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1507\/endocrj.45.Suppl_S89","article-title":"Calcitonin gene-related peptide (CGRP) as a GH secretagogue in rat and human pituitary tumoral cells","volume":"45","author":"Nakamura","year":"1998","journal-title":"Endocr J"},{"key":"10.1016\/j.jaad.2023.03.057_bib4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4103\/mmj.mmj_185_18","article-title":"Role of insulin-like growth factor-1 receptor in female androgenetic alopecia","volume":"33","author":"Hamam","year":"2020","journal-title":"Menoufia Med J"},{"issue":"3","key":"10.1016\/j.jaad.2023.03.057_bib5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/cen.12040","article-title":"Scalp hair loss after transsphenoidal adenomectomy in patients with acromegaly","volume":"79","author":"Yamada","year":"2013","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223006990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223006990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:23:34Z","timestamp":1759274614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223006990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0190962223006990"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.03.057","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medications affecting the insulin-like growth factor 1\/growth hormone axis, including teprotumumab, somatostatin analogs, and anti-calcitonin gene-related peptide monoclonal antibodies, are associated with elevated reporting odds of alopecia in women: A pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.03.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}